Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001395064-20-000122)

Filing Details

Accession Number:: 0001395064-20-000122
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-06-30 20:24:39
Reporting Period:: 2020-06-30

Accepted Time:: 2020-06-30 20:24:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1693415	Translate Bio Inc.	TBIO	Pharmaceutical Preparations (2834)	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1395064	Takeda Pharmaceutical Co Ltd	1-1, Nihonbashi-Honcho 2-Chome Chuo-Ku, Tokyo M0 103-8668		No	No	Yes	No
1745009	Shire Human Genetic Therapies, Inc.	300 Shire Way Lexington MA 02421		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-06-30	6,824,992	$20.68	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

This statement is being filed jointly by Shire Human Genetic Therapies, Inc. and Takeda Pharmaceutical Company Limited.
These shares are owned directly by Shire Human Genetic Therapies, Inc., which is an indirect wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Takeda Pharmaceutical Company Limited is an indirect beneficial owner of the reported securities.